Results 291 to 300 of about 103,481 (331)
Some of the next articles are maybe not open access.
Neuroprotection by dopamine agonists
Journal of neural transmission. Supplementum, 1994Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative ...
Lange, Klaus W. +5 more
openaire +4 more sources
Journal of Neural Transmission, 2019
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
P.-A. Löschmann, R. Horowski
openaire +3 more sources
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
P.-A. Löschmann, R. Horowski
openaire +3 more sources
Dopamine agonist‐responsive depression [PDF]
Psychogeriatrics, 2013 AbstractDopaminergic dysfunction is implicated in the pathophysiology of treatment‐resistant depression. In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment‐resistant depression, and discuss the underlying mechanisms by which these ...
Hiroshi Kunugi, Hiroaki Hori
openaire +2 more sources
Medical Clinics of North America, 1999
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Neuroprotection and Dopamine Agonists
2004Parkinson’s disease is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. Accumulating evidence indicates that apoptosis contributes to the cell death in Parkinson’s disease patients’ brain.
Zvezdan Pirtošek, Dušan Flisar
openaire +3 more sources
Dopamine agonists in Parkinson’s disease
Expert Opinion on Investigational Drugs, 2003Levodopa (LD), the immediate precursor of dopamine, is the most effective agent in the treatment of Parkinson's disease (PD). While quite successful in treating the primary motor deficits of PD, most patients eventually develop LD-related motor fluctuation, dyskinesias and other adverse effects associated with chronic LD therapy.
Ron Tintner, Joseph Jankovic
openaire +3 more sources
Dopamine Agonists in the Treatment of Schizophrenia
1986Publisher Summary Behavioral, neurochemical, ligand binding, and single cell unit recording studies suggest the existence of two distinct classes of dopamine (DA) receptors: autoreceptors, which are present on the membranes of dopamine neurons, and postsynaptic receptors located on the neurons with which dopamine neurons synapse.
DEL ZOMPO, MARIA +3 more
openaire +5 more sources
Neuroprotection and dopamine agonists
Neurology, 2002Several factors are known to be capable of inducing relatively selective dopaminergic cell death in the substantia nigra and inducing the clinical features that characterize Parkinson's disease (PD). Neuronal toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce parkinsonism in human and animal models, and rotenone, another ...
openaire +3 more sources
Dopamine agonists for cocaine dependence
2003Cocaine is a major drug of abuse. Cocaine dependence is a common and serious condition, which has become nowadays a substantial public health problem. There is a wide and well documented range of consequences associated to chronic use of this drug, such as medical, psychological and social problems, including the spread of infectious diseases (e.g ...
Lima Reisser Aa +3 more
openaire +5 more sources
Dopamine agonists and Parkinson's disease
Clinical Neurology and Neurosurgery, 1984The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
D.B. Calne, K. Burton
openaire +3 more sources